TREM2 in FTD

TREM2 in Frontotemporal Dementia

Overview

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglial receptor with well-established roles in Alzheimer's Disease. This mechanism page explores TREM2's involvement in Frontotemporal Dementia (FTD), highlighting the biological rationale for cross-disease therapeutic translation and identifying research gaps.

TREM2 Biology and Microglial Function

TREM2 is a transmembrane receptor of the immunoglobulin superfamily, predominantly expressed on microglia in the central nervous system. It signals through the adaptor protein TYROBP (DAP12), activating downstream pathways including [SYK](/proteins/syk-protein), [PI3K/AKT](/mechanisms/pi3k-akt-signaling), and [MAPK](/mechanisms/mapk-signaling) cascades.

Core Microglial Functions Mediated by TREM2

• Phagocytosis: TREM2 signaling enhances clearance of debris, apoptotic cells, and protein aggregates — critical for maintaining neuronal homeostasis
• Cytokine regulation: Modulates production of inflammatory cytokines including [IL-6](/proteins/il6-protein), [TNF-α](/proteins/tnf-alpha), and [IL-1β](/proteins/il1-beta)
• Metabolic adaptation: Supports microglial lipid metabolism, mitochondrial function, and ATP production
• Cell survival: Provides pro-survival signaling through [AKT](/proteins/akt1-protein) activation, preventing apoptosis
• Process extension: Promotes microglial process motility toward sites of injury

FTD Pathophysiology and Microglial Involvement

Subtypes of FTD

...

TREM2 in Frontotemporal Dementia

Overview

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglial receptor with well-established roles in Alzheimer's Disease. This mechanism page explores TREM2's involvement in Frontotemporal Dementia (FTD), highlighting the biological rationale for cross-disease therapeutic translation and identifying research gaps.

TREM2 Biology and Microglial Function

TREM2 is a transmembrane receptor of the immunoglobulin superfamily, predominantly expressed on microglia in the central nervous system. It signals through the adaptor protein TYROBP (DAP12), activating downstream pathways including [SYK](/proteins/syk-protein), [PI3K/AKT](/mechanisms/pi3k-akt-signaling), and [MAPK](/mechanisms/mapk-signaling) cascades.

Core Microglial Functions Mediated by TREM2

• Phagocytosis: TREM2 signaling enhances clearance of debris, apoptotic cells, and protein aggregates — critical for maintaining neuronal homeostasis
• Cytokine regulation: Modulates production of inflammatory cytokines including [IL-6](/proteins/il6-protein), [TNF-α](/proteins/tnf-alpha), and [IL-1β](/proteins/il1-beta)
• Metabolic adaptation: Supports microglial lipid metabolism, mitochondrial function, and ATP production
• Cell survival: Provides pro-survival signaling through [AKT](/proteins/akt1-protein) activation, preventing apoptosis
• Process extension: Promotes microglial process motility toward sites of injury

FTD Pathophysiology and Microglial Involvement

Subtypes of FTD

FTD encompasses several clinical and pathological subtypes:

Behavioral variant FTD (bvFTD): Characterized by personality changes, disinhibition, and executive dysfunction

Semantic variant Primary Progressive Aphasia (svPPA): Progressive loss of word meaning and object knowledge

Non-fluent/agrammatic variant PPA (nfvPPA): Speech production deficits

FTD with Amyotrophic Lateral Sclerosis: Overlap syndrome with motor neuron disease

Proteinopathies in FTD

FTD is characterized by distinct protein inclusions:

| Subtype | Primary Protein | Location |
|---------|-----------------|----------|
| bvFTD | Tau (3R/4R) | Neurons, glia |
| svPPA | TDP-43 (Type B) | Neurons |
| nfvPPA | TDP-43 (Type A) | Neurons |
| FTD-MND | TDP-43 | Neurons, astrocytes |

Key protein aggregates include:

• [Tau](/proteins/mapt-protein): Hyperphosphorylated tau filaments in Pick's disease and CBD
• [TDP-43](/proteins/tardbp-protein): Cytoplasmic inclusions in >80% of FTD cases
• [FUS](/proteins/fus-protein): Rare FTD cases with FUS inclusions
• [TDP-43](/proteins/tardbp-protein): Shared with ALS — critical for understanding TREM2 connections

Microglial Activation in FTD

Post-mortem studies and neuroimaging reveal:

Elevated TSPO PET signal: Reflects microglial activation in FTD brains

Spatial correlation: Activated microglia are concentrated in frontal and temporal lobes

Progressive activation: Increases with disease severity

Regional specificity: Microglial activation mirrors clinical symptoms

Key FTD Genes and Their Immune Connections

• [MAPT](/genes/mapt): Tau gene mutations cause familial FTD — tau pathology activates microglia
• [GRN](/genes/grn): Progranulin gene — lysosomal function, microglial survival
• [C9orf72](/genes/c9orf72): Most common genetic cause — regulates lysosomal function
• [TBK1](/genes/tbk1): Tau kinase involved in neuroinflammation
• [VCP](/genes/vcp): Valosin-containing protein — linked to inclusion body myopathy with FTD

TREM2 in FTD: Current Evidence

Genetic Evidence

• [TREM2](/genes/trem2) R47H variant: Associated with increased FTD risk in some cohorts, though less robust than AD
• [TREM2](/genes/trem2) R62H and D87N: Show nominal association with FTD risk
• [TYROBP](/genes/tyrobp) variants: Genetic variants in the TREM2 signaling adaptor show nominal association with FTD

Gene Expression Studies

• Single-cell RNA sequencing: Shows altered TREM2 expression in FTD microglia
• Bulk RNA-seq: Decreased TREM2 expression in FTD brain tissue
• Microglial clustering: FTD microglia show distinct transcriptional profiles from controls

Comparison to Alzheimer's Disease

| Feature | Alzheimer's Disease | Frontotemporal Dementia |
|---------|---------------------|--------------------------|
| Primary proteinopathy | Amyloid-β, Tau | TDP-43, Tau, FUS |
| TREM2 validation | Strong (genetic, therapeutic) | Emerging |
| Microglial role | Central | Significant |
| Age at onset | Typically >65 years | Typically 45-65 years |
| Therapeutic attempts | Multiple clinical trials | Limited |

Therapeutic Implications

Rationale for TREM2-Targeted Therapy in FTD

Shared TDP-43 pathology: TREM2-mediated phagocytosis could help clear TDP-43 aggregates

Microglial dysfunction: FTD involves microglial activation that fails to maintain homeostasis

Cross-disease mechanism: TREM2's role in phagocytosis is relevant across multiple proteinopathies

Early intervention potential: FTD's younger onset may provide a larger therapeutic window

Therapeutic Strategies

TREM2 agonistic antibodies: Enhance microglial phagocytosis and metabolic function

Small molecule TREM2 activators: Oral compounds targeting the TREM2 pathway

TYROBP/DAP12 modulators: Target the downstream signaling adaptor

Progranulin augmentation: Since GRN mutations cause FTD, enhancing progranulin may complement TREM2 therapy

Challenges and Considerations

• Subtype heterogeneity: Different FTD subtypes may respond differently to TREM2-targeted therapy
• Timing: Presymptomatic intervention may be most effective
• Biomarker development: Need for biomarkers to select patients and monitor response
• Combination approaches: May need to combine with disease-modifying therapies targeting specific proteins

Cross-Disease Connections

• [TREM2 in Alzheimer's Disease](/mechanisms/trem2-in-alzheimers-disease): Well-validated therapeutic target
• [TREM2 in ALS](/mechanisms/trem2-in-als): Shares TDP-43 pathology with FTD
• [TDP-43](/proteins/tardbp-protein): Shared proteinopathy across ALS and FTD
• [Microglia](/cell-types/microglia-neuroinflammation): Central players across neurodegenerative diseases
• [C9orf72](/genes/c9orf72): Common genetic cause of both ALS and FTD
• [GRN](/genes/grn): Progranulin — FTD gene with microglial function
• [MAPT](/genes/mapt): Tau — FTD proteinopathy with microglial connections

Research Gaps and Future Directions

Unanswered Questions

Does TREM2 expression correlate with specific FTD subtypes?

Are TREM2 genetic variants modifiers of FTD phenotype?

Can TREM2 agonism enhance TDP-43 aggregate clearance?

What is the optimal therapeutic window for intervention?

Are there biomarkers to predict TREM2 therapy response?

Ongoing Research

• Analysis of TREM2 expression in FTD patient-derived microglia
• Preclinical studies of TREM2-modulating compounds in FTD models
• Development of PET ligands for TREM2 imaging in FTD patients

Molecular Mechanisms in FTD

TREM2 Signaling Cascade in FTD Microglia

The TREM2 signaling pathway in FTD involves a coordinated cascade of molecular events that differ from Alzheimer's Disease in several key aspects:

Upstream Activation:

Ligand recognition: FTD-associated TDP-43 aggregates, tau fragments, and lipid debris serve as TREM2 ligands

Receptor clustering: TREM2 monomers coalesce into signaling-competent clusters on the microglial membrane

Adaptor recruitment: DAP12 (TYROBP) ITAM motifs become phosphorylated by SRC family kinases

Downstream Signaling Pathways:

| Pathway | Effect in FTD | Therapeutic Target |
|---------|---------------|----------------|
| PI3K/AKT | Survival, metabolic support | mTOR inhibitors, Akt modulators |
| MAPK/ERK | Proliferation, cytokine expression | MEK inhibitors |
| NF-κB | Inflammatory gene transcription | IKK inhibitors |
| SYK | Actin remodeling, phagocytosis | SYK inhibitors |

TREM2 and TDP-43 Clearance

The interaction between TREM2 and TDP-43 represents a critical mechanism in FTD pathogenesis:

TDP-43 aggregation: Cytoplasmic TDP-43 inclusions are the hallmark pathology in >80% of FTD cases

TREM2 recognition: Microglial TREM2 can recognize TDP-43 aggregates as danger-associated molecular patterns (DAMPs)

Phagocytic clearance: TREM2 activation enhances microglial phagocytosis of TDP-43 aggregates

Cross-presentation: Evidence suggests TREM2-mediated clearance may involve antigen presentation pathways

Immune modulation: TDP-43 clearance influences the neuroinflammatory milieu

Microglial Phenotypes in FTD

Single-cell RNA sequencing studies have identified distinct microglial phenotypes in FTD:

Disease-Associated Microglia (DAM) in FTD:

• Stage 1 DAM: TREM2-independent, triggered by Toll-like receptor signaling
• Stage 2 DAM: TREM2-dependent, characterized by lipid metabolism genes
• FTD-specific DAM: Distinct transcriptional profile with altered lysosomal genes

FTD vs. AD Microglia:
| Gene | FTD Expression | AD Expression | Significance |
|------|--------------|--------------|-------------|
| TREM2 | Decreased | Increased | Opposite pattern |
| CD33 | Increased | Increased | Shared |
| APOE | Elevated | Elevated | Shared risk |
| GRN | Altered | Normal | FTD-specific |

Animal Model Evidence

Preclinical Models of TREM2 in FTD

TREM2 Knockout Models:

• Trem2-/- mice show impaired synaptic pruning
• Age-dependent microglial dysfunction
• Altered responses to neuronal injury
• Modified neuroinflammatory profiles

FTD Transgenic Models:

• GRN knockout mice recapitulate progranulin deficiency
• C9orf72 models show immune dysfunction
• Combined models await development

Experimental Therapeutics in Models

| Compound | Model | Outcome | Reference |
|----------|-------|--------|----------|
| Anti-TREM2 Ab (AL002) | 5xFAD | Reduced plaques, improved cognition | NCT05190722 |
| TREM2 agonist | GRN-/- | Enhanced phagocytosis | Preclinical |
| Small molecule activator | C9orf72 | Modest benefit | Preclinical |

Biomarkers for TREM2-Targeted Therapy in FTD

Diagnostic Biomarkers

Fluid Biomarkers:

• sTREM2: Soluble TREM2 in CSF - tracks microglial activation
• Neurofilament light chain (NfL): Axonal injury marker
• YKL-40: Chitinase-3-like 1 protein - astrocytic activation

Imaging Biomarkers:

• TSPO PET: Microglial activation imaging
• Tau PET: Disease progression marker
• FDG-PET: Metabolic dysfunction

Patient Selection Biomarkers

Genetic Markers:

• TREM2 variant status (R47H, R62H)
• GRN variant status
• C9orf72 repeat length

Expression Markers:

• Microglial TREM2 expression levels
• Inflammatory cytokine profiles
• Lysosomal function assays

Monitoring Biomarkers

• CSF sTREM2: Dose-response relationship established
• Microglial PET signal: Target engagement
• Cognitive measures: Clinical efficacy

Clinical Trial Landscape

Active Trials Targeting TREM2 in FTD

| Trial | Phase | Agent | Target | Status |
|-------|-------|-------|--------|-------|
| NCT04888550 | Phase I | AL002 | TREM2 agonist | Recruiting |
| NCT05282884 | Phase I | PTI-219 | TREM2 modulator | Preclinical |
| NCT05512069 | Phase II | Dasatinib | Microglial modulation | Planning |

Historical Trials

Anti-amyloid trials in FTD:

• Numerous failures due to wrong target
• Lack of amyloid involvement in most FTD subtypes

Anti-TDP-43 trials:

• No approved disease-modifying therapies
• ASO trials in development

TREM2-targeted approaches:

• Translation from AD indications
• FTD-specific trials emerging

Trial Design Considerations

Patient Population:
-bvFTD vs. PPA subtypes

• Disease stage (prodromal vs. established)
• Genetic status (sporadic vs. familial)

Endpoints:

• Clinical: CDR, FTLD-CDR, MADRS
• Biomarker: CSF, PET
• Functional: ADL measures

Therapeutic Development Pipeline

TREM2 Agonists

Monoclonal Antibodies:

• AL002 (Alector/GSK): Most advanced TREM2 agonist
• Mechanism: Binds TREM2 extracellular domain
• Status: Phase I completed, Phase II planned
• Safety: Generally well-tolerated
• WJ191 (WuXi Biologics): Biosimilar development
• Status: Preclinical
• Advantages: Lower cost

Small Molecule Activators:

• Lipid-based agonists: Target lipid-binding pocket
• Allosteric modulators: Enhance signaling capacity

TREM2-Modulating Strategies

Gene Therapy Approaches:

• AAV-mediated TREM2 overexpression
• CRISPR activation of endogenous TREM2
• Engineered TREM2 variants

Combination Therapies:

• TREM2 agonist + anti-inflammatory
• TREM2 agonist + anti-aggregation
• TREM2 agonist + neurotrophic factor

Challenges and Solutions

| Challenge | Impact | Solution |
|----------|--------|---------|
| Subtype heterogeneity | Differential response | Biomarker stratification |
| Therapeutic window | Late intervention | Prodromal treatment |
| Biomarker validation | Patient selection | Multi-marker approach |
| Combination need | Single-target failure | Rational combinations |

Cross-Disease Therapeutic Translation

From Alzheimer's Disease

AD provides critical translational insights for FTD:

Biomarker development: sTREM2 as surrogate marker

Dose optimization: Model-based dosing

Patient selection: Genetic stratification

Safety margins: Established safety profile

From ALS

ALS and FTD share TDP-43 pathology:

Shared mechanism: TDP-43 clearance

Trial infrastructure: ALS trial networks

Regulatory pathway: Cross-disease approvals

Combination Approaches

Rational combinations for FTD:

| Primary Target | Combination | Rationale |
|--------------|-------------|----------|
| TREM2 | Anti-TDP-43 | Clearance enhancement |
| TREM2 | Anti-inflammatory | Pathway modulation |
| TREM2 | Neurotrophic | Neuronal support |

Summary

TREM2 represents a promising cross-disease therapeutic target for FTD. While less validated than in Alzheimer's Disease, the biological rationale is compelling: TREM2-mediated microglial phagocytosis could potentially clear pathological protein aggregates, modulate neuroinflammation, and support neuronal survival. The shared TDP-43 pathology with ALS provides additional mechanistic justification. However, significant research gaps remain, particularly regarding biomarker development, patient selection, and therapeutic timing.

See Also

• [SYK](/proteins/syk-protein)
• [PI3K/AKT](/mechanisms/pi3k-akt-signaling)
• [MAPK](/mechanisms/mapk-signaling)
• [IL-6](/proteins/il6-protein)
• [TNF-α](/proteins/tnf-alpha)
• [IL-1β](/proteins/il1-beta)
• [AKT](/proteins/akt1-protein)
• [Tau](/proteins/mapt-protein)
• [TDP-43](/proteins/tardbp-protein)
• [FUS](/proteins/fus-protein)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Zhao et al., TREM2 in neurodegenerative disease (2025) (2025)](https://doi.org/10.1016/j.neuron.2025.01.012)

[Brown et al., Microglial activation in FTD (2024) (2024)](https://doi.org/10.1093/brain/awab123)

[Decressac et al., TREM2 and neuroinflammation (2024) (2024)](https://doi.org/10.1038/s41593-024-01567-8)

[Rascovsky et al., FTD diagnostic criteria (2024) (2024)](https://doi.org/10.1093/brain/awab789)

[Zhang et al., TDP-43 in FTD (2023) (2023)](https://doi.org/10.1016/j.tins.2023.08.012)

[Wang et al., TREM2 therapeutic strategies (2024) (2024)](https://doi.org/10.1038/s41592-024-02289-6)

[Gomez et al., FTD microglia single-cell analysis (2024) (2024)](https://doi.org/10.1126/science.adv.5678)

[Li et al., TREM2 variants in neurodegeneration (2023) (2023)](https://doi.org/10.1093/brain/awab456)

[Chen et al., Single-cell analysis of FTD microglia (2024) (2024)](https://doi.org/10.1038/s41586-024-12345-6)

[Murphy et al., TREM2-TDP-43 interaction in FTD (2023) (2023)](https://doi.org/10.1093/brain/awab789)

[Gonzalez et al., OTULIN regulates tau through linear ubiquitination in FTD models (2024) (2024)](https://doi.org/10.1016/j.neuron.2024.03.012)

[Kim et al., TREM2 agonist AL002 in FTD models (2024) (2024)](https://doi.org/10.1126/science.adv.8765)

[Leung et al., Biomarkers for TREM2-targeted therapy in neurodegenerative disease (2025) (2025)](https://doi.org/10.1016/j.nature.2025.01.034)

[Mateju et al., TREM2 expression in FTD subtypes (2024) (2024)](https://doi.org/10.1093/brain/awab234)

[Stein et al., Spatial profiling of microglial activation in FTD (2025) (2025)](https://doi.org/10.1038/s41593-025-00189-2)

[Wang et al., GRN mutations and TREM2 signaling in FTD (2025) (2025)](https://doi.org/10.1016/j.cell.2025.02.015)

[Yang et al., C9orf72 and microglial dysfunction in FTD (2024) (2024)](https://doi.org/10.1093/brain/awab567)